SAN FRANCISCO, April 13, 2020 /PRNewswire/ -- Sutro
Biopharma, Inc. (NASDAQ: STRO), today announced that the company
has been invited to present updated clinical data from its STRO-002
antibody-drug conjugate (ADC) at the upcoming AACR Virtual Annual
Meeting 2020. The submitted abstract and a virtual poster
presentation, which will consist of further updated data
accompanied by a video presentation from Dr. Wendel Naumann of The Levine Cancer Institute,
will be available on demand on the AACR website (aacr.org) on
Monday, April 27. Additionally, Sutro
will host a conference call and live audio webcast on Monday, April 27 to discuss the STRO-002 clinical
data, details of the call will be provided within the next
week.
The AACR presentation will include updated initial dose
escalation safety and efficacy data from the company's ongoing
Phase I study of STRO-002 in ovarian and endometrial cancer.
STRO-002 is a novel ADC targeting the clinically validated folate
receptor-α (FolRα), an antigen known to be overexpressed in ovarian
cancer. Sutro discovered and manufactures STRO-002 using its
proprietary XpressCF+™ cell-free protein synthesis technology.
Poster Presentation Details:
STRO-002-GM1, a First in Human, Phase 1 Study of STRO-002, an
anti-Folate Receptor-alpha (FRα) Antibody Drug
Conjugate (ADC), in Patients with Advanced
Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC),
including Fallopian Tube or Primary Peritoneal Cancers
Date: Monday, April 27, 2020
Abstract Number: 9807
The abstract title was published today on the AACR website. The
submitted abstract and the virtual poster presentation will be also
accessible through the Clinical/Scientific Presentation and
Publication Highlights page of the News section of the company's
website at www.sutrobio.com on the day of the poster
presentation.
About Sutro Biopharma
Sutro Biopharma, Inc., located
in South San Francisco, is a
clinical-stage drug discovery, development and manufacturing
company. Using precise protein engineering and rational design,
Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis
platform XpressCF® and site-specific conjugation platform,
XpressCF+™, led to the discovery of STRO-001 and STRO-002, Sutro's
first two internally-developed ADCs. STRO-001 is a CD74-targeting
ADC currently being investigated in a Phase I clinical trial of
patients with advanced B-cell malignancies, including multiple
myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug
Designation by the FDA for multiple myeloma in October 2018. STRO-002 is a folate receptor alpha
(FolRα)-targeting ADC, currently being investigated in a Phase I
clinical trial of patients with ovarian and endometrial cancers.
This is the second product candidate to be evaluated in clinical
trials resulting from Sutro's XpressCF® and XpressCF+™
technology platforms. A third program, CC-99712 (BCMA-targeting
ADC), which is part of Sutro's collaboration with Bristol-Myers
Squibb (formerly Celgene Corporation), is enrolling patients for
its Phase I clinical trial of patients with multiple myeloma.
Sutro's proprietary technology was responsible for the discovery
and manufacturing of CC-99712, for which Bristol-Myers Squibb has
worldwide development and commercialization rights. Sutro is
entitled to development and regulatory milestone payments and
tiered royalties from Bristol-Myers Squibb for this BCMA ADC.
Sutro is dedicated to transforming the lives of cancer patients
by creating medicines with improved therapeutic profiles for areas
of unmet need.
To date, Sutro has designed cytokine-based immuno-oncology
therapies, ADCs, vaccines and bispecific antibodies primarily
directed at clinically-validated targets for which the current
standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and
development of potential first-in-class and best-in-class molecules
through rapid and systematic evaluation of protein
structure-activity relationships to create optimized homogeneous
product candidates.
In addition to developing its own oncology pipeline, Sutro is
collaborating with select pharmaceutical and biotech companies to
discover and develop novel, next-generation therapeutics. As the
pace of clinical development accelerates, Sutro and its partners
are developing therapeutics designed to more efficiently kill
tumors without harming healthy cells.
Additional multimedia content from Sutro regarding STRO-001 and
STRO-002 can be found here and here.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to
learn more about our passion for changing the future of
oncology.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated preclinical and clinical development
activities, potential benefits of the company's product candidates
and platform and potential market opportunities for the company's
product candidates. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Although the company believes that the expectations
reflected in such forward-looking statements are reasonable, the
company cannot guarantee future events, results, actions, levels of
activity, performance or achievements, and the timing and results
of biotechnology development and potential regulatory approval is
inherently uncertain. Forward-looking statements are subject to
risks and uncertainties that may cause the company's actual
activities or results to differ significantly from those expressed
in any forward-looking statement, including risks and uncertainties
related to the company's ability to advance its product candidates,
the receipt and timing of potential regulatory designations,
approvals and commercialization of product candidates, the impact
of the COVID-19 pandemic on the Company's business, clinical trial
sites, supply chain and manufacturing facilities, the Company's
ability to maintain and recognize the benefits of certain
designations received by product candidates, the timing and results
of preclinical and clinical trials, the company's ability to fund
development activities and achieve development goals, the company's
ability to protect intellectual property, and the Company's
commercial collaborations with third parties and other risks and
uncertainties described under the heading "Risk Factors" in
documents the company files from time to time with the Securities
and Exchange Commission. These forward-looking statements speak
only as of the date of this press release, and the company
undertakes no obligation to revise or update any forward-looking
statements to reflect events or circumstances after the date
hereof.
Investor Contacts
John Graziano
Solebury Trout
+1 646-378-2942
jgraziano@soleburytrout.com
Xuan Yang
Solebury Trout
+1 646-378-2975
xyang@soleburytrout.com
Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Travis Kruse
Russo Partners
(212) 845-4272
travis.kruse@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/sutro-biopharma-to-present-updated-clinical-data-for-its-stro-002-antibody-drug-conjugate-at-the-aacr-virtual-annual-meeting-on-april-27-2020-301039639.html
SOURCE Sutro Biopharma